NASDAQ:DRNA

Dicerna Pharmaceuticals Competitors

$29.33
+0.80 (+2.80 %)
(As of 04/16/2021 11:03 AM ET)
Add
Compare
Today's Range
$28.92
Now: $29.33
$30.21
50-Day Range
$22.91
MA: $26.50
$29.51
52-Week Range
$16.50
Now: $29.33
$29.90
Volume9,844 shs
Average Volume818,360 shs
Market Capitalization$2.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33

Competitors

Dicerna Pharmaceuticals (NASDAQ:DRNA) Vs. MRTX, BBIO, RARE, ARWR, GWPH, and ASND

Should you be buying DRNA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Dicerna Pharmaceuticals, including Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), and Ascendis Pharma A/S (ASND).

Mirati Therapeutics (NASDAQ:MRTX) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk and Volatility

Mirati Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Mirati Therapeutics and Dicerna Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,414.97$-213,260,000.00($5.69)-28.00
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66

Dicerna Pharmaceuticals has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.9% of Mirati Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Mirati Therapeutics and Dicerna Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics151002.56
Dicerna Pharmaceuticals00703.00

Mirati Therapeutics presently has a consensus price target of $218.5714, suggesting a potential upside of 37.21%. Dicerna Pharmaceuticals has a consensus price target of $39.1429, suggesting a potential upside of 33.46%. Given Mirati Therapeutics' higher probable upside, equities analysts clearly believe Mirati Therapeutics is more favorable than Dicerna Pharmaceuticals.

Profitability

This table compares Mirati Therapeutics and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

BridgeBio Pharma (NASDAQ:BBIO) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares BridgeBio Pharma and Dicerna Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million201.80$-260,590,000.00($2.48)-22.16
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66

Dicerna Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BridgeBio Pharma and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

Insider and Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for BridgeBio Pharma and Dicerna Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01902.90
Dicerna Pharmaceuticals00703.00

BridgeBio Pharma presently has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than BridgeBio Pharma.

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66
Ultragenyx Pharmaceutical$103.71 million70.15$-402,730,000.00($7.36)-14.76

Dicerna Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Ultragenyx Pharmaceutical-119.19%-50.69%-26.87%

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Dicerna Pharmaceuticals and Ultragenyx Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00703.00
Ultragenyx Pharmaceutical06802.57

Dicerna Pharmaceuticals presently has a consensus price target of $39.1429, indicating a potential upside of 33.46%. Ultragenyx Pharmaceutical has a consensus price target of $131.20, indicating a potential upside of 20.73%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Dicerna Pharmaceuticals is more favorable than Ultragenyx Pharmaceutical.

Summary

Dicerna Pharmaceuticals beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Profitability

This table compares Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00703.00
Arrowhead Pharmaceuticals021002.83

Dicerna Pharmaceuticals presently has a consensus price target of $39.1429, indicating a potential upside of 33.46%. Arrowhead Pharmaceuticals has a consensus price target of $85.3077, indicating a potential upside of 26.27%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dicerna Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66
Arrowhead Pharmaceuticals$87.99 million79.69$-84,550,000.00($0.84)-80.43

Arrowhead Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GW Pharmaceuticals (NASDAQ:GWPH) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for GW Pharmaceuticals and Dicerna Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Dicerna Pharmaceuticals00703.00

GW Pharmaceuticals currently has a consensus target price of $204.0909, indicating a potential downside of 6.69%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than GW Pharmaceuticals.

Insider and Institutional Ownership

81.0% of GW Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 3.1% of GW Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares GW Pharmaceuticals and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

Risk & Volatility

GW Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares GW Pharmaceuticals and Dicerna Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million22.02$-9,020,000.00($0.24)-911.38
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66

GW Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

GW Pharmaceuticals beats Dicerna Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Dicerna Pharmaceuticals and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Ascendis Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million93.66$-120,460,000.00($1.76)-16.66
Ascendis Pharma A/S$14.98 million441.02$-244,180,000.00($5.25)-23.41

Dicerna Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dicerna Pharmaceuticals and Ascendis Pharma A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00703.00
Ascendis Pharma A/S011102.92

Dicerna Pharmaceuticals currently has a consensus target price of $39.1429, indicating a potential upside of 33.46%. Ascendis Pharma A/S has a consensus target price of $187.6667, indicating a potential upside of 52.69%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Dicerna Pharmaceuticals.

Summary

Dicerna Pharmaceuticals beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Ad Legacy Research
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.

Dicerna Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$159.30+3.0%$8.31 billion$3.34 million-20.69News Coverage
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.95+1.5%$8.19 billion$40.56 million-16.11
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.67+0.8%$7.34 billion$103.71 million-24.75Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.56+0.6%$7.06 billion$87.99 million-80.43
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.73+0.0%$6.86 billion$311.33 million-127.17Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$122.91+1.0%$6.67 billion$14.98 million-14.97Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92+0.2%$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03+1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.52+1.6%$5.77 billion$380.83 million-9.15Analyst Report
Allakos logo
ALLK
Allakos
1.7$105.33+2.7%$5.74 billionN/A-38.44Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95+0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.48+0.7%$5.50 billion$4.84 billion-691.22
Schrödinger logo
SDGR
Schrödinger
1.3$78.18+0.2%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$78.95+0.6%$5.20 billion$1.00 billion-11.96Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56+1.7%$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13+0.8%$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.06+1.1%$4.28 billion$204.89 million-36.33
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.08+1.4%$4.10 billion$806.43 million-9.50Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$76.06+2.1%$3.99 billion$1.11 billion24.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28+1.4%$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83+2.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.74+4.7%$3.78 billionN/A-21.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.99+2.7%$3.60 billionN/A-6.20Analyst Report
Analyst Revision
News Coverage
Gap Down
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.11+1.3%$3.53 billion$114.62 million-7.71Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62+3.1%$3.47 billion$136.47 million-12.55
LEGN
Legend Biotech
1.2$25.40+1.6%$3.43 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14+0.3%$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96+1.6%$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.07+1.2%$3.34 billion$26.52 million-8.02
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37+0.5%$3.29 billion$36.13 million-70.70
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$113.23+3.6%$3.17 billionN/A-56.33Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.65+0.6%$3.15 billion$1.17 billion-42.72
Arvinas logo
ARVN
Arvinas
1.5$62.57+0.7%$3.08 billion$42.98 million-24.44
MorphoSys logo
MOR
MorphoSys
0.3$22.75+1.9%$3.05 billion$80.43 million108.34Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88+5.5%$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.27+1.2%$2.89 billion$901.90 million-23.72
Organogenesis logo
ORGO
Organogenesis
1.0$21.22+6.5%$2.89 billion$260.98 million-353.67
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.43+1.3%$2.85 billion$644.77 million-10.76
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10+2.3%$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18+4.5%$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67+0.3%$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.50+2.0%$2.69 billion$306.49 million25.28
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28+3.4%$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78+4.4%$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88+1.1%$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76+3.6%$2.48 billion$15 million-17.68Unusual Options Activity
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$148.93+0.0%$2.47 billion$120.28 million-150.43Analyst Report
Decrease in Short Interest
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50+0.2%$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$50.89+4.0%$2.41 billion$33.94 million-87.74Gap Up
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.